A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer

PURPOSE: This dedicated QTc study was designed to evaluate the effect of the mammalian target of rapamycin inhibitor, ridaforolimus, on the QTc interval in patients with advanced malignancies. METHODS: We conducted a fixed-sequence, single-blind, placebo-controlled study. Patients (n = 23) received...

Descripción completa

Detalles Bibliográficos
Autores principales: Lush, Richard M., Patnaik, Amita, Sullivan, Daniel, Papadopoulos, Kyriakos P., Trucksis, Michele, McCrea, Jacqueline, Cerchio, Kristine, Li, Xiaodong, Stroh, Mark, Selverian, Diana, Orford, Keith, Ebbinghaus, Scot, Agrawal, Nancy, Iwamoto, Marian, Wagner, John A., Tolcher, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456920/
https://www.ncbi.nlm.nih.gov/pubmed/22878520
http://dx.doi.org/10.1007/s00280-012-1942-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3456920/
https://www.ncbi.nlm.nih.gov/pubmed/22878520
http://dx.doi.org/10.1007/s00280-012-1942-7

Ejemplares similares